Abstract
The rapid advancement of targeted therapeutics has significantly improved treatment precision and efficacy in oncology and metabolic disorders. This article integrates key developments in four areas: highly selective PPAR modulators for metabolic and inflammatory diseases; CRISPR-engineered T-cell receptor therapies targeting the KRAS G12D mutation in cancer; strategies to enhance antitumor immunity through glutamine metabolism modulation in the tumor microenvironment; and a novel system for analyzing coformulated biologics. These innovations highlight the integration of metabolic modulation, immune system engineering, and advanced biologic formulation, paving the way for more effective and personalized therapeutic approaches.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
